News

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week. Japan’s National Institute of Biomedical Innovation (NIBIO), GHTC member Aeras, and Create Vaccine Company have entered an agreement to collaborate on preclinical and clinical development of new tuberculosis vaccines. The partnership will advance vaccine candidates with the NIBIO technology through preclinical studies, with the goal of eventually testing candidates at clinical trial stages. According to SciDev, the UK Department for International Development (DFID)’s budget for research and development has fallen under the current government. DFID’s research budget in 2011-2012 was £11 million—or about US$18 million—below the £237 million that was available in 2009-2010, prior to the coalition government coming to power. In response to a US congressman, Roger Glass—director of the Fogarty International Center at the National Institutes of Health (NIH)—made the case for global health research supported by NIH. Glass writes: “In almost every branch of medicine, research overseas has allowed us to advance our discoveries faster, cheaper, and more efficiently than we ever could have at home. We are leaders in global health because we have been able to reach out and engage others to do studies that are locally relevant but can have clear implications for us at home. Global health research truly is the new frontier of science.” amfAR, The Foundation for AIDS Research has launched a new initiative—called Countdown to a Cure—aimed at funding a “broadly applicable cure for HIV by 2020.” The initiative plans to invest $100 million in cure research over the next six years.

In this guest post, Kari Stoever, vice president of External Affairs at Aeras, writes about how mine workers are disproportionately affected by tuberculosis (TB) and why there’s an urgent need for new tools against this deadly disease. Deep underground, in cramped quarters, with silica dust floating through the air, the hacking cough of a miner with TB is a familiar sound. Mine workers in sub-Saharan Africahave the highest rates of TB in the world, with wide spread consequences in communities throughout the region. It is estimated that mining is responsible for as much as 760,000 new cases of TB each year, making it the single biggest driver of the TB epidemic after HIV. Not only does TB contribute to the dangers of mine work, but it also decreases economic viability. Each year, the mining industry loses around $570 million in productivity costs, and miners lose $320 million per year in lost wages, due to TB. Photo credit: David Rockhkind/Aeras Fifteen South African nations, known as the Southern African Development Community (SADC), have pledged to confront the TB epidemic in the mines through investing in treatment and control programs. While these efforts are to be commended, the ultimate solution is to invest in new vaccines to prevent TB. Recently published study results in the New England Journal of Medicine found that when South African miners were given universal isoniazid preventive therapy—intended to prevent the progression of latent TB to active disease—there was no lasting effect on TB incidence among mineworkers. Because rates of TB are so high in this community, significantly reducing the spread of TB will only be possible with transformative new technologies to effectively halt transmission. What needs to happen for the mining industry to support research and development (R&D) for new TB vaccines? Governments must unlock resources for TB R&D. Health experts must educate policymakers about the need for new tools—such as vaccines, drugs, and diagnostics. Mining industry decision-makers must partner with research organizations to advance TB R&D to protect their workforce and to improve productivity and reduce operating costs. Supporting R&D for new tools to diagnose, treat, and prevent tuberculosis will be an integral part of making southern African mines safer. This week, Aeras is at Investing in African Mining Indaba, the world’s largest mining investment event, to discuss potential ways to partner with governments and mining industry officials to address the TB threat. View the slideshow and check out the info graphic to learn more about the deadly combination of tuberculosis and mining, and join us in spreading the word and advocating for new TB vaccines to protect mineworkers.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week. In this year’s State of the Union, President Obama mentioned “federally-funded research” and recognized that “there are entire industries based on vaccines that stay ahead of drug-resistant bacteria.” While a modest statement, the President’s recognition of these important US contributions to global health is significant. Last week during the World Health Organization Executive Board meeting, Member States met to discuss moving forward on eight demonstration projects that would look at new ways to spur research and development (R&D) for diseases that affect populations in low- and middle-income countries. However, some advocates were disappointed that the topic of alternative funding mechanisms for global health R&D was not substantively debated. The US Agency for International Development (USAID) announced this week that the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 Tenofovir gel trial was the winner of the agency’s Science and Technology Pioneers Prize. The prize recognizes “excellence in the use of science and technology to solve development challenges.” This is the first year USAID has awarded the prize. The Swiss Federal Department of Home Affairs and the Federal Department of Foreign Affairs, and the Bill & Melinda Gates Foundation have signed a Memorandum of Understanding to improve access to health interventions through the strengthening of regulatory systems. The partnership could improve and accelerate access to health interventions and therapeutic products in resource-constraint countries.

This post was originally featured on path.org on January 27, 2013 and was written by PATH’s Drug Development program. The post is the first in a three-part series. To see future posts in this series, check out path.org. In December, PATH hosted a Transformative Innovations event in Palo Alto, CA with a panel discussion on ways that public and private sectors can work together to save lives. In three installments, we’ll bring you excerpts of the discussion from our panelists Ponni Subbiah and Anurag Mairal, program leaders of PATH’s Drug Development and Technology Solutions programs, respectively, and Joel Segre, an independent strategy consultant focused on product development and distribution challenges in global health. In our first post, Ponni shares her insights into what makes a partnership successful and reflects on the potential for innovation coming from nontraditional sources. Q: One of the shifting paradigms of the future is that innovation will be multidirectional and come from anywhere in the world. What impacts do you see this having on solving global health challenges? PS: It’s quite exciting because it makes our work truly global, not a pushed-down approach to solving global health problems. We’re transitioning from a world where interventions were done to and for countries to a world where innovation happens with countries. Every sector is realizing that you’re missing opportunities by not tapping into local talent. Even though many of our end users lack access to education, their insights, experiences, and knowledge are invaluable to creating a successful end product. The playing field is becoming more even, and partnerships are now happening at the local level. The younger generation, especially, is much more global and informed in outlook than previous generations, and they’re all about innovation and creativity. The question is, how do we capitalize on that energy and harness it to accomplish global health goals? Traditionally, especially in the private sector, many local affiliate leaders of international companies were from high-income countries. This is changing with the recognition that developing a talent pipeline at the local level is critical for long-term success within a region or country. Similarly, one of PATH’s goals is to identify leaders on the ground to build a stronger presence in countries. We need strong leaders who are well connected and influential so we can build strong and fruitful relationships with governments and civil-society organizations.   Dr. Ponni Subbiah with Wolfgang Laux from Sanofi, PATH's manufacturing partner on the project to create semisynthetic artemisinin. Photo: PATH Q: PATH has pioneered the idea that innovation is not just about technology but about the way in which you engage with partners, the business models you deploy, and the way you think about creating markets. What lessons have you learned about how to do this effectively, how to make sure that partnerships result in real impact, rather than more talk and transaction costs? PS: One of the most critical lessons we’ve learned is that for a partnership to be successful, we have to do the due diligence at the beginning when we’re selecting partners. We need to make sure that the organization we partner with has not only the technical capabilities and areas of expertise needed for the project’s success but also institutional support for the nonprofit aims of the project, especially from senior leadership. It’s important to have those senior leaders on board to be champions for the humanitarian side of an endeavor and to help us drive the project forward. Once a partner is selected, sitting down from the get-go and having a clear discussion about what each organization hopes to get from the project, what the incentives are, deliverables, etc. is key. These kinds of big-picture discussions, aside from the day-to-day communications that take place, should occur at set intervals, at least every six months, because these variables may change over the course of the project. If the goals of a project change, it will require some course correction to get back on track. Another critical element of a successful partnership is building trust and transparency. Though we’re all very connected technologically speaking, I find that it’s still important to have face-to-face meetings. Connecting in person and getting to know someone’s personality and work style changes the way we work together, usually for the better. I think it fosters more open interactions and makes people more willing to be flexible and cooperative. In this field especially, when our partners are all over the globe, we have to be cognizant of creating enough opportunities for face-to-face meetings. We try to provide time and support to make sure team members get this opportunity to connect. What goes hand in hand with building trust and transparency is the ability to have tough discussions. Teams that actually go through some tough discussions and overcome them are the great teams; teams that don’t challenge each other and avoid putting issues on the table never get to that great team level. Each partner brings a different strength and area of expertise to the partnership, and accordingly, each partner is under different institutional demands and pressures. We have to make choices about the battles we pick and where and how we can compromise to move projects forward, given that everyone is committed to a high-quality end result. As a nonprofit, some of the most important qualities we can bring to the table are expertise in global health, flexibility, and patience. We have to be accustomed to change. With the start and end of each phase of a project, new partners may come aboard and others may become less involved in day-to-day activities. Each project team has to do the same thing—understand where each partner is coming from, identify the critical areas that need further discussion, and then work together to problem solve. For more Innovation. Transformation. Inspiration., stay tuned to the Drug Development blog for the next two installment with Dr. Anurag Mairal and Joel Segre, and follow them on Twitter and Facebook. More information PATH’s Drug Development program PATH’s Technology Solutions program The NGO challenge: stay ahead of the curve Semisynthetic artemisinin achieves WHO prequalification